Anti-Hu CD97 FITC

*Wobus M, Vogel B, Schmücking E, Hamann J, Aust G: N-glycosylation of CD97 within the EGF domains is crucial for epitope accessibility in normal and malignant cells as well as CD55 ligand binding. Int J Cancer. 2004 Dec 10;112 (5) :815-22., URL: http://www.ncbi.nlm.nih.gov/pubmed/15386373

*Wang T, Tian L, Haino M, Gao JL, Lake R, Ward Y, Wang H, Siebenlist U, Murphy PM, Kelly K: Improved antibacterial host defense and altered peripheral granulocyte homeostasis in mice lacking the adhesion class G protein receptor CD97. Infect Immun. 2007 Mar;75 (3) :1144-53., URL: https://www.ncbi.nlm.nih.gov/pubmed/17158902?ordin, *Abbott RJ, Spendlove I, Roversi P, Fitzgibbon H, Knott V, Teriete P, McDonnell JM, Handford PA, Lea SM: Structural and functional characterization of a novel T cell receptor co-regulatory protein complex, CD97-CD55. J Biol Chem. 2007 Jul 27;282 (30) :22023-32., URL: https://www.ncbi.nlm.nih.gov/pubmed/17449467?ordin, *Galle J, Sittig D, Hanisch I, Wobus M, Wandel E, Loeffler M, Aust G: Individual cell-based models of tumor-environment interactions: Multiple effects of CD97 on tumor invasion. Am J Pathol. 2006 Nov;169 (5) :1802-11., URL: https://www.ncbi.nlm.nih.gov/pubmed/17071601?ordin, *Visser L, de Vos AF, Hamann J, Melief MJ, van Meurs M, van Lier RA, Laman JD, Hintzen RQ. Expression of the EGF-TM7 receptor CD97 and its ligand CD55 (DAF) in multiple sclerosis. J Neuroimmunol. 2002 Nov;132 (1-2) :156-63., URL: https://www.ncbi.nlm.nih.gov/pubmed/12417446?ordin